Syngene partners with Sapient to expand discovery offerings

Syngene International, a subsidiary of Indian biotechnology major Biocon, says that it will offer fully-integrated drug discovery services  by partnering with USA-based Sapient Discovery.

Syngene provides integrated chemistry, biology and biologics services  to support development programs of pharmaceutical and biotechnology  companies worldwide on a platform of confidentiality and intellectual  property rights protection.

The companies intend to provide a highly-integrated platform for  structure-based drug discovery with a one-stop shop for structure-guided  discovery, chemistry, biology and structural biology capabilities. This  arrangement is crucial at a time when cost-reductions and efficiency in  the drug discovery process is driving companies to look for suitable  out-sourcing partners, the firms say.